|Better Therapeutics Inc., of San Francisco||BT-001||Prescription digital therapeutic||Treatment of type 2 diabetes||Enrolled the first patient in its pivotal study; will enroll 650 individuals randomized to receive standard of care with or without BT-001; the primary efficacy endpoint of the study is difference in the mean change from baseline in A1c between the 2 groups after 90 days of treatment|
|Diacarta Inc., of Richmond, Calif.||Rapid SARS-CoV-2 variant test||Uses XNA-based Molecular Clamping Technology||Detects SARS-CoV-2 variants||278 previously tested SARS-CoV-2 positive samples were analyzed in a study; the SARS-CoV-2 Spike-gene D614G mutation was detected in 58 of the 139 samples collected in January 2021 (41.7%) and in 78 of the 139 samples collected in February (56.1%); while the N501Y mutation was not detected in the samples from January, 7 of the February samples tested positive for both the N501Y and D614G mutations|
|Elixir Medical Corp., of Milpitas, Calif.||Dynamx coronary bioadaptor system||Metal implant with a drug-eluting bioresorbable polymer coating||Supports the coronary artery during healing and improves vessel function||Said the BIOADAPTOR randomized controlled trial is expanding to centers in Belgium and Germany; the study is enrolling 444 patients from 30 centers in Europe and Japan treated with the Dynamx Bioadaptor in a 1:1 randomization to Resolute Onyx|
|Solace Therapeutics Inc., of Framingham, Mass.||Vesair bladder control system||Compressible, air-filled balloon placed in the bladder||Treatment of stress urinary incontinence||Enrolled the first patient in the VESAIR clinical trial to test the safety and efficacy in the U.S.|
For more information about individual companies and/or products, see Cortellis.